Novartis notifies about Phase III COMBI-I study to treat skin cancer
By Nikita Chaurasia  Date: 2020-08-24

Novartis notifies about Phase III COMBI-I study to treat skin cancer

Reportedly, Novartis made an announcement that the COMBI-I study in its third phase that does evaluation of investigational immunotherapy spartalizumab (PDR001), combined with the targeted therapies Mekinist (trametinib) and Tafinlar (dabrafenib) did not produce a primary result of progression-free, investigator-assessed survival.

As per the trusted sources, the trail was conducted on untreated patients with metastatic (Stage IV) BRAF V600 or unresectable (Stage IIIC) mutation-positive cutaneous melanoma, in comparison with Tafinlar + Mekinist treatment alone. Tafinlar and Mekinist are medicines prescribed in combination to treat patients with skin cancer- melanoma.

John Tsai, MD, Chief Medical Officer and Head of Global Drug Development at Novartis states that although the COMBI-I trial did not get to its primary outcome, the report’s analysis offers some important insights of its part like the investigational immunotherapy spartalizumab could possibly contribute to the future cancer therapy combinations. Besides this, it also highlights the significance of Tafinlar + Mekinist for these patients as estimated in the past.

He further added that Novartis is fully dedicated towards curing melanoma patients through ongoing study and they would continue to provide the approved combination therapy Tafinlar + Mekinist to patients across the globe.

He added that they at Novartis extend gratitude to the patients and investigators who took part in the COMBI-I study and claimed that their collaboration has raised understanding of spartalizumab and its potential role in future cancer treatments at Novartis.

Reportedly, COMBI-I study investigators and people at Novartis will continue to analyze the data to gain more information from the results, which are likely to be taken forward to a presentation at a future medical meeting.

Novartis continues to search for more uses of immunotherapy in cancer treatment, along with the latest ongoing development of spartalizumab, across a plethora of tumors.  

Source credits-

https://www.novartis.com/news/media-releases/novartis-provides-update-phase-iii-study-evaluating-investigational-spartalizumab-pdr001-combination-tafinlar-mekinist-advanced-melanoma

About Author

Nikita Chaurasia    

Nikita Chaurasia

An accomplished professional in the field of content development, playing with words comes naturally to Nikita Chaurasia. After completing her post-graduate MBA degree in Advertising and PR, Nikita worked across numerous content-driven verticals, undertaking diverse r...

Read More

More News By Nikita Chaurasia

Top Glove shuts down factories amidst rising COVID-19 cases in Malaysia
Top Glove shuts down factories amidst rising COVID-19 cases in Malaysia
By Nikita Chaurasia

  The company has reportedly ceased its operations after 2453 employees tested positive for the Coronavirus. The company’s shares plummeted by 7.5% after the Malaysian government ordered to shut down 28 of its factories. As per relia...

Belcan becomes software engineering services firm Avista’s new owner
Belcan becomes software engineering services firm Avista’s new owner
By Nikita Chaurasia

Belcan, LLC, a leading supplier of engineering, technical recruiting, supply chain, and information technology (IT) services to various sectors, reportedly announced the acquisition of Avista, Inc., a safety-critical and mission-critical software eng...

Swisscom to install Nokia FastMile 5G Receivers in Switzerland
Swisscom to install Nokia FastMile 5G Receivers in Switzerland
By Nikita Chaurasia

Nokia, the leading Finnish telecommunications giant, has reportedly announced that Swisscom, a renowned Swiss telecommunications firm, would install Nokia FastMile 5G Receivers across rural areas of Switzerland to provide high speed broadband service...

CDC funds $1.5 Mn for co-robots; aims to reduce worker exposure
CDC funds $1.5 Mn for co-robots; aims to reduce worker exposure
By Nikita Chaurasia

Projects developed through this grant is expected to be used in developing collaborative robots for use in the manufacturing and healthcare industries. With over more than 5000 workers losing their lives due to work-related injury in the United ...

Telia & Ericsson join hands to launch Estonia’s first 5G network
Telia & Ericsson join hands to launch Estonia’s first 5G network
By Nikita Chaurasia

Telia, a Swedish multinational telecommunications company, will be the first one to begin 5G in the country which will be powered by Ericsson 5G technology. With this move, the company will be enabling innovation for businesses and provide high-speed...